Joint detection kit for miRNA marker of lung cancer

Abstract

The invention discloses a joint detection kit for miRNA marker of lung cancer. The joint detection kit comprises reverse transcription primers shown as SEQ ID NO.1 to 2 as well as primer pairs shown as SEQ ID NO.3 to 4 and SEQ ID NO.5 to 6. The invention also discloses application of the reverse transcription primers shown as SEQ ID NO.1 to 2 as well as the primer pairs shown as SEQ ID NO.3 to 4 and SEQ ID NO.5 to 6 in preparation of reagents for screening the lung cancer. The joint detection kit disclosed by the invention can be used for screening of the lung cancer and clinical auxiliary diagnosis of the lung cancer and has the advantages of high detection sensitivity, good specificity a good clinical application prospect.

Description

technical field [0001] The invention relates to a combined detection kit for miRNA markers of lung cancer. Background technique [0002] Lung cancer is a common malignant tumor, and its morbidity and mortality rate ranks first among other malignant tumors in the world. In the United States in 2015, approximately 86,380 men and 86,380 women died of lung cancer. In China in 2015, the incidence and mortality of lung cancer were 0.0733% and 0.061%, respectively, ranking first among cancer-related diseases. Since the symptoms of early lung cancer patients are not obvious, most patients are already in the middle and late stages when they are diagnosed. Therefore, improving the early diagnosis of lung cancer plays a vital role in the prevention and treatment of lung cancer. At present, the early diagnosis of lung cancer mainly relies on imaging technology and the detection of tumor markers. Low-dose computed tomography (LDCT) has high sensitivity and is the most common means of ...

AI Technical Summary

Problems solved by technology

However, CT false positives are high, detection costs are high, and radiation has potential harm to the human body

Images